Printer Friendly

Diplomat markets advanced kidney treatment, CABOMETYX tablets.

M2 EQUITYBITES-January 16, 2018-Diplomat markets advanced kidney treatment, CABOMETYX tablets

(C)2018 M2 COMMUNICATIONS http://www.m2.com

Specialist pharmacy Diplomat Pharmacy Inc (NYSE:DPLO) reported on Monday that it is now distributing CABOMETYX (cabozantinib) tablets under an expanded indication to include first-line therapy for patients with advanced renal cell carcinoma

CABOMETYX was initially approved as a second-line therapy for advanced RCC in 2016. However, CABOMETYX was recently approved by the Food and Drug Administration as a first-line therapy indicated to treat patients with advanced renal cell carcinoma (RCC).

The company added that the manufacturer of CABOMETYX is Exelixis Inc.

RCC is a type of cancer in which malignant cells form in the lining of tubules of the kidney. According to the American Cancer Society, RCC is the most common form of kidney cancer found in adults, accounting for nearly 90 percent of all kidney cancers.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Jan 16, 2018
Words:157
Previous Article:KNOT Offshore declares distribution of USD0.52 per unit for Q4 2017.
Next Article:Skanska awarded SEK330m contract to build a new hospital building in Karlskrona, Sweden.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters